While her career has been filled with highlights, she takes the most pride in having two Alzheimer's drugs, Namenda and Leqembi; she is one of few people to have achieved such a feat.
WILMINGTON, NC, June 14, 2024 /24-7PressRelease/ -- Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to present Joanne Bell with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Joanne Bell celebrates many years' experience in her professional network, and has been noted for achievements, leadership qualities, and the credentials and successes she has accrued in her field. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Driven to pursue a career in the sciences, Dr. Bell received a bachelor's degree from Franklin & Marshall College in 1976 and a Master of Arts from the University of Hartford three years later. Subsequently, she received a PhD in neuroscience from Washington University in St. Louis and completed a postdoctoral fellowship in neuropsychopharmacology at Duke University Medical Center. During her postdoctoral studies, she developed an interest in neurotoxicity. However, her lab mentor encouraged her to join the Alzheimer's disease research collaborative center study due to her expertise in biochemical analysis. Upon further contemplation, Dr. Bell pursued it and became one of the first investigators in modern day in post-mortem brain autopsies in Alzheimer's disease.
Over the years, Dr. Bell gained valuable expertise as a senior director at Forest Laboratories, where she worked from 2002 until 2006 and launched Namenda for moderate to severe Alzheimer's disease, before joining Pfizer, Inc. in a similar role. Likewise, she honed her expertise as vice president of clinical development and neuroscience for Syneos Health. A seasoned Alzheimer's disease specialist, she excels as the executive global medical director of Eisai U.S. Neurology, through which she translates clinical scientific and technical data into something more digestible to practicing physicians who will prescribe the medication they are prescribing. Due to her vast knowledge, Dr. Bell and her team are working on Leqembi, the first mononuclear amyloid beta-directed antibody converted from accelerated to traditional approval for the treatment of early disease Alzheimer's. Leqembi has the first mechanism of action known to halt disease progression. In addition to her clinical duties, Dr. Bell is involved in mentoring efforts.
Driven to remain abreast of changes in the field, Dr. Bell aligns herself with the Alzheimer's Association International Conference, where she served as chair for professional interest areas and a submission reviewer. While her career has been filled with highlights, she takes the most pride in having two Alzheimer's drugs, Namenda and Leqembi; she is one of few people to have achieved such a feat. Throughout her career, she has worked on 17 different Alzheimer's compounds in her lifetime. Looking forward, Dr. Bell looks to become the chief operating officer of a small biotechnology company, focusing on neurodegenerative disease.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
# # #